webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mal-PEG4-bis-PEG3-methyltetrazine

  CAS No.:   Cat No.: BADC-01275   Purity: ≥95% 4.5  

Mal-PEG4-bis-PEG3-methyltetrazine is a cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Mal-PEG4-bis-PEG3-methyltetrazine

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C65H95N15O20
Molecular Weight
1406.54
Shipping
Room temperature
Shipping
Store at -20 °C, keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Solubility
10 mm in DMSO
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Mal-PEG4-bis-PEG3-methyltetrazine is a highly functionalized compound used in advanced bioconjugation and targeted drug delivery applications. This compound features a maleimide (Mal) group, a polyethylene glycol (PEG4) spacer, a bis-PEG3 linker, and a methyltetrazine moiety. The maleimide group is highly reactive with thiol groups, allowing for stable covalent bonding with biomolecules such as antibodies, peptides, or proteins. The PEG spacers provide solubility, reduced immunogenicity, and enhanced pharmacokinetics, making it an ideal candidate for in vivo applications. The methyltetrazine group is useful for bioorthogonal chemistry, enabling selective conjugation or activation in complex biological environments. This compound is widely used in targeted cancer therapies and imaging applications.

A primary application of Mal-PEG4-bis-PEG3-methyltetrazine is in the development of antibody-drug conjugates (ADCs) for cancer treatment. By attaching cytotoxic drugs or imaging agents to antibodies via the maleimide group, the compound ensures targeted delivery to cancer cells that express specific surface markers. The PEG4 spacer improves solubility and stability in circulation, enhancing the pharmacokinetics of the conjugate. The bis-PEG3 linker further increases flexibility, allowing for more efficient drug delivery. The methyltetrazine group enables bioorthogonal reactions, such as the Staudinger ligation or tetrazine-trans-cyclooctene reactions, which can be used for precise drug release in the tumor microenvironment or for imaging. This targeted approach minimizes off-target effects and increases the therapeutic index of the drug.

Mal-PEG4-bis-PEG3-methyltetrazine is also employed in bioorthogonal chemistry for selective labeling and imaging of biomolecules. The methyltetrazine group can react with trans-cyclooctene (TCO) or other tetrazine-based reagents in living systems, allowing for the covalent labeling of specific proteins, peptides, or nucleic acids without interference from natural functional groups. This selective reactivity makes it an excellent tool for labeling in vivo, enabling real-time imaging and tracking of biomolecules in living organisms. The PEG spacers ensure that the labeled molecules maintain their solubility and native structure, which is critical for accurate imaging and analysis. This application is particularly valuable in molecular imaging, proteomics, and studying cellular interactions.

Furthermore, Mal-PEG4-bis-PEG3-methyltetrazine is utilized in the development of targeted delivery systems for other therapeutic agents, including small molecule drugs and RNA-based therapies. The bioorthogonal reactivity of the methyltetrazine group allows for the controlled release of drugs at specific sites within the body. This feature is particularly beneficial for overcoming challenges such as poor tissue penetration and off-target toxicity associated with traditional drug delivery methods. The PEG spacers enhance the overall stability and solubility of the conjugate, improving its effectiveness in vivo. By enabling precise drug activation or release at the target site, this compound offers significant potential in advancing targeted therapies, particularly for diseases such as cancer and genetic disorders.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Azido-PEG5-propionic acid | Azido-PEG4-propionic acid | Fmoc-Ala-Ala-Asn(Trt)-OH | m-PEG8-COOH | Bis-PEG1-NHS ester | m-PEG2-NHS ester | Alkyne-PEG2-iodide | Mal-PEG4-Val-Cit-PAB-OH | Amino-PEG8-propionic acid | Azido-PEG2-PFP ester | Mal-PEG4-bis-PEG3-methyltetrazine
Send Inquiry
Verification code
Inquiry Basket